Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...
Outsourcing-pharma2d
Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
BioSpace2d
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
health.wusf.usf.edu1d
Florida grand jury investigating COVID vaccines finds 'serious issues' but no crimes
The grand jury, convened at the request of Gov. Ron DeSantis, recommended policy changes including increasing transparency ...
FierceBiotech4h
Lilly crafts deal for up to 5 new ALS antibodies with UK biotech Alchemab
Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...
3 trial readouts that could shake up the obesity market this year
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.B9uuF-Zi.js ...
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ('IGC Pharma' or the 'Company') announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...
CliniOps Announces Strategic Partnership With Indegene to Accelerate Clinical Trials
Avik Pal, CliniOps' CEO, expressed enthusiasm for the collaboration, stating, 'This partnership is an exciting opportunity for CliniOps and Indegene to complement each other's strengths, to ultimately ...